



Corrigendum

Corrigendum to “Association of White Matter Integrity with Executive Function and Antidepressant Treatment Outcome in Patients with Late-Life Depression” [The American Journal of Geriatric Psychiatry 29 (2021) 1188-1198]

Xiaofu He, Ph.D., Elena Pueraro, B.A., Yoojean Kim, B.A., Carolina Montes Garcia, B.A., Ben Maas, B.A., Jongwoo Choi, M.A., Dakota A. Egglefield, Ph.D., Sophie Schiff, M.A., Joel Sneed, Ph.D., Patrick J. Brown, Ph.D., Adam Brickman, Ph.D., Steven P. Roose, M.D., Bret R. Rutherford, M.D.

ARTICLE INFO

Article history:

Received September, 16 2022

Accepted September, 19 2022

The authors regret an omission from the published study methodology. As described in the published manuscript, current treatment with

antidepressant medication was an exclusion criterion for the clinical trial whose data were analyzed. We wish to clarify that while current treatment with

DOI of original article: <http://dx.doi.org/10.1016/j.jagp.2021.01.004>

From the Department of Psychiatry, Vagelos College of Physicians and Surgeons (XH, PJB, SPR, BRR), Columbia University, New York, NY; New York State Psychiatric Institute (XH, EP, YK, CMG, JC, PJB, SPR, BRR), New York, NY; Department of Neurology (BM, AB), Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, G.H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY; and the The Graduate Center (DAE, SS, JS), City University of New York, New York, NY; Queens College, City University of New York, New York, NY. Send correspondence and reprint requests to Xiaofu He, PhD, Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, The New York State Psychiatric Institute, New York, NY. e-mail: xh2170@cumc.columbia.edu

© 2022 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

<https://doi.org/10.1016/j.jagp.2022.09.007>

antidepressant medication was an exclusion criterion, otherwise eligible individuals who were taking ineffective antidepressant medication were allowed to sign consent and participate in the study so long as they completed a study-supervised taper and discontinuation of the medication prior to beginning the

study medication. Of the 71 analyzed participants in this publication, 18 individuals completed a study-supervised taper and discontinuation of ineffective antidepressant medication.

The authors would like to apologize for any inconvenience caused.